3.4.13.22: D-Ala-D-Ala dipeptidase
This is an abbreviated version!
For detailed information about D-Ala-D-Ala dipeptidase, go to the full flat file.
Word Map on EC 3.4.13.22
-
3.4.13.22
-
dipeptide
-
enterococci
-
vancomycin-resistant
-
peptidoglycan
-
medicine
-
d-alanyl-d-lactate
-
d-ala-d-lactate
-
glycopeptide
-
faecium
-
carboxypeptidase
-
zinc-dependent
-
cell-wall
-
zinc-containing
-
toyocaensis
-
tetrahedral
-
depsipeptide
-
uv-vis
-
l-ala-l-ala
-
thiophenol
-
hedgehog
-
enterica
-
albus
-
vanhax
-
kinact
-
d,d-dipeptidase
-
phosphinate
-
synthesis
-
analysis
- 3.4.13.22
- dipeptide
-
enterococci
-
vancomycin-resistant
- peptidoglycan
- medicine
-
d-alanyl-d-lactate
- d-ala-d-lactate
- glycopeptide
- faecium
- carboxypeptidase
-
zinc-dependent
-
cell-wall
-
zinc-containing
- toyocaensis
-
tetrahedral
-
depsipeptide
-
uv-vis
- l-ala-l-ala
- thiophenol
-
hedgehog
- enterica
-
albus
-
vanhax
-
kinact
- d,d-dipeptidase
- phosphinate
- synthesis
- analysis
Reaction
Synonyms
AAD, D-, D-dipeptidase, D-Ala-D-Ala amino dipeptidase, D-Ala-D-Ala dipeptidase, D-Ala-D-Ala dipeptidase VanX, D-Ala-D-Ala-dipeptidase, D-alanyl-D-alanine dipeptidase, M15.011, MAB1843, Vancomycin B-type resistance protein vanX, VanX, VanXY, VanXYc
ECTree
Advanced search results
Application
Application on EC 3.4.13.22 - D-Ala-D-Ala dipeptidase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
analysis
medicine
synthesis
although catalytically ineffecient, the VanX substrate D-leucine-p-nitroanilide is an alternative substrate for VanX because it can be monitored directly and assayed spectrophotometrically which facilitates the routine analysis of enzyme catalysis and the screening discovery of potential VanX inhibitors. In addition, it is with leucine in its D form that possible activities from other contaminated species (other than VanX) in Escherichia coli JM109 are greatly reduced. Moreover, D-leucine-p-nitroanilide needs essentially no sophisticated synthetic chemistry for preparation
analysis
-
continuous assay of VanX in vitro and in vivo from hydrolysis of D-Ala-D-Ala, based on the heat-rate changes measured with isothermal titration calorimetry
enzyme may be a target for drug design to reverse clinical vancomycin resistance
medicine
-
key drug target in circumventing clinical vancomycin resistance
medicine
-
Enterecoccus faecium carrying plasmid pHVH-V1511 is capable of nosocomial transmission and may develop clinical resistance to vancomycin. Strains may not be detected using standard culture methods for vancomycin-resistant enterococci
medicine
Mycobacterium abscessus is an pulmonary pathogen in humans. The enzyme induces dendritic maturation via toll-like receptor 4 and its downstream signaling pathways, such as the mitogen-activated protein kinase and nuclear factor kappa B pathways. Enzyme-treated dendritic cells stimulate the proliferation of T cells and promote Th1 polarization
medicine
-
Mycobacterium abscessus is an pulmonary pathogen in humans. The enzyme induces dendritic maturation via toll-like receptor 4 and its downstream signaling pathways, such as the mitogen-activated protein kinase and nuclear factor kappa B pathways. Enzyme-treated dendritic cells stimulate the proliferation of T cells and promote Th1 polarization
-
-
novel cell breakage method based on VanX. The D-Ala-D-Ala dipeptidase encoded in a vancomycin-resistant VanA gene cluster, exhibits a strong cell lysis activity when expressed in isolation in Escherichia coli. Coexpression of VanX with the target protein causes cell autolysis and release of the cellular content into the culture medium. Application of this strategy for two model proteins, a green fluorescent protein variant and Gaussia luciferase, and optimization of the autolysis conditions and coexpression vectors shows that the fluorescence activity of green fluorescent protein variant collected from the medium is identical to that of green fluorescent protein variant purified by conventional methods. Cell breakage by VanX-mediated autolysis is very simple to implement and will efficiently complement traditional methods
synthesis
-
strong bacteriolysis occurrs when isolated VanX is expressed in Escherichia coli at temperatures lower than 30°C. No cell lysis is observed when VanX is expressed, even in large quantities, in the cell inclusion bodies at 37°C, suggesting that a natively folded VanX is required for lysis. In addition, VanX mutants with suppressed dipeptidase activity do not lyse Escherichia coli cells, confirming that bacteriolysis originates from the dipeptidase activity of VanX. There are also shape changes in Escherichia coli cells undergoing VanX-mediated lysis, these changes may be classified into three classes: bursting, deformation, and leaking fluid